BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26122536)

  • 1. The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma.
    Venza M; Visalli M; Oteri R; Agliano F; Morabito S; Teti D; Venza I
    Int Immunopharmacol; 2015 Sep; 28(1):313-21. PubMed ID: 26122536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
    Venza I; Visalli M; Oteri R; Teti D; Venza M
    Int Immunopharmacol; 2014 Aug; 21(2):439-46. PubMed ID: 24946096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells.
    Venza M; Visalli M; Beninati C; Benfatto S; Teti D; Venza I
    Int Immunopharmacol; 2016 Nov; 40():235-243. PubMed ID: 27620505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
    Bangert A; Cristofanon S; Eckhardt I; Abhari BA; Kolodziej S; Häcker S; Vellanki SH; Lausen J; Debatin KM; Fulda S
    Oncogene; 2012 Nov; 31(44):4677-88. PubMed ID: 22266862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
    Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
    Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
    Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
    Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.
    Ricci MS; Jin Z; Dews M; Yu D; Thomas-Tikhonenko A; Dicker DT; El-Deiry WS
    Mol Cell Biol; 2004 Oct; 24(19):8541-55. PubMed ID: 15367674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
    Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP.
    Zeise E; Weichenthal M; Schwarz T; Kulms D
    J Invest Dermatol; 2004 Oct; 123(4):746-54. PubMed ID: 15373780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP.
    Zhang T; Wang X; He D; Jin X; Guo P
    Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ku70 acetylation and modulation of c-Myc/ATF4/CHOP signaling axis by SIRT1 inhibition lead to sensitization of HepG2 cells to TRAIL through induction of DR5 and down-regulation of c-FLIP.
    Kim MJ; Hong KS; Kim HB; Lee SH; Bae JH; Kim DW; Dao TT; Oh WK; Kang CD; Kim SH
    Int J Biochem Cell Biol; 2013 Mar; 45(3):711-23. PubMed ID: 23247197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition.
    Morales JC; Ruiz-Magaña MJ; Ruiz-Ruiz C
    Mol Immunol; 2007 Apr; 44(10):2587-97. PubMed ID: 17257681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
    Schuchmann M; Schulze-Bergkamen H; Fleischer B; Schattenberg JM; Siebler J; Weinmann A; Teufel A; Wörns M; Fischer T; Strand S; Lohse AW; Galle PR
    Oncol Rep; 2006 Jan; 15(1):227-30. PubMed ID: 16328060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
    Song JH; Song DK; Herlyn M; Petruk KC; Hao C
    Clin Cancer Res; 2003 Sep; 9(11):4255-66. PubMed ID: 14519653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L).
    Li W; Zhang X; Olumi AF
    Cancer Res; 2007 Mar; 67(5):2247-55. PubMed ID: 17332355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.
    Morales JC; Ruiz-Magaña MJ; Carranza D; Ortiz-Ferrón G; Ruiz-Ruiz C
    Cancer Lett; 2010 Nov; 297(1):91-100. PubMed ID: 20580868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.